GlassScriptPhysician profile
Ravinder Gandhi
NPI 1003995689
$5,140.47
in general payments reported to CMS, 2019-2025
44 companies · $950 in 2025
The $950 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $228 · 2020: $154 · 2021: $253 · 2022: $860 · 2023: $1,390 · 2024: $1,305 · 2025: $950.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,504 · Education: $141.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,503.56 |
| Education | $141.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $501.19 | 2020-2024 | Yupelri |
| Glaxosmithkline, LLC. | $489.49 | 2019-2025 | Nucala, Trelegy Ellipta |
| Harmony Biosciences LLC | $447.49 | 2020-2025 | Wakix |
| Regeneron Healthcare Solutions, INC. | $385.19 | 2022-2025 | Dupixent |
| Astrazeneca Pharmaceuticals LP | $307.30 | 2019-2025 | Breztri, Tezspire |
| Ucb, INC. | $284.38 | 2023-2025 | Nayzilam, Rystiggo, Briviact |
| 3b Medical, INC. | $258.09 | 2023 | Luna |
| Insmed, INC. | $212.97 | 2019-2025 | Brinsupri, Arikayce |
| Jazz Pharmaceuticals INC. | $168.97 | 2023-2024 | |
| Biogen, INC. | $166.37 | 2022-2024 | Vumerity, Tysabri, Avonex |
| Inogen, INC. | $153.85 | 2022-2024 | Inogen One G5 Oxygen Concentrator - Bluetooth, Inogen |
| Sk Life Science, INC. | $147.17 | 2023-2024 | |
| Actelion Pharmaceuticals US, INC. | $130.23 | 2022-2025 | Uptravi, Opsumit |
| Emd Serono, INC. | $120.55 | 2019-2024 | Mavenclad |
| Genentech USA, INC. | $115.72 | 2019-2024 | Enspryng, Ocrevus |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $107.04 | 2023-2025 | Vest Therapy Und, (8874) Incourage |
| Neurelis, INC. | $99.56 | 2023-2025 | Valtoco |
| Genzyme Corporation | $98.62 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $93.13 | 2025 | Ofev, Jascayd |
| Avadel Cns Pharmaceuticals, LLC | $70.82 | 2024-2025 | Lumryz |
| Ani Pharmaceuticals, INC. | $62.28 | 2024-2025 | Purified Cortrophin Gel |
| Alexion Pharmaceuticals, INC. | $59.81 | 2023-2024 | Ultomiris |
| Mallinckrodt Hospital Products INC. | $52.88 | 2022 | |
| Amgen INC. | $51.98 | 2022-2024 | Tezspire, Tavneos |
| United Therapeutics Corporation | $48.71 | 2025 | Tyvaso |
| Verona Pharma, INC. | $45.26 | 2025 | Ohtuvayre |
| Alnylam Pharmaceuticals INC. | $44.36 | 2023-2024 | Amvuttra, Givlaari |
| Tanabe Pharma America, INC. | $43.45 | 2024 | |
| Grifols USA, LLC | $42.31 | 2020-2025 | Prolastin-C Liquid |
| Pulmonx Corporation | $39.87 | 2022-2025 | Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console, Zephyr Endobronchial Valve |
| Neurocrine Biosciences, INC. | $30.93 | 2024 | Ingrezza |
| Merck Sharp & Dohme LLC | $29.39 | 2022-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $25.84 | 2020 | |
| Nevro Corp. | $25.77 | 2023 | Senza |
| Viatris Specialty LLC | $24.13 | 2025 | Yupelri |
| Inspire Medical Systems, INC. | $22.87 | 2023 | Inspire |
| Celgene Corporation | $19.43 | 2025 | Zeposia |
| Upsher-Smith Laboratories LLC | $17.57 | 2021 | |
| Electromed, INC. | $17.04 | 2022 | |
| Lundbeck LLC | $16.42 | 2023 | Rexulti |
| Pfizer INC. | $16.32 | 2024 | |
| Sunovion Pharmaceuticals INC. | $16.02 | 2020 | |
| Shockwave Medical, INC | $15.06 | 2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Lilly USA, LLC | $14.64 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ravinder Gandhi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.